Market Analysts see ProQR Therapeutics N.V. [PRQR] gaining to $5. Time to buy?

ProQR Therapeutics N.V. [NASDAQ: PRQR] jumped around 1.05 points on Thursday, while shares priced at $2.70 at the close of the session, up 63.64%. The company report on December 22, 2022 that ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The archived webcast will be available for approximately 30 days following the presentation date.

ProQR Therapeutics N.V. stock is now -66.29% down from its year-to-date (YTD) trading value. PRQR Stock saw the intraday high of $3.10 and lowest of $2.5501 per share. The company’s 52-week high price is 8.60, which means current price is +409.43% above from all time high which was touched on 01/04/22.

Compared to the average trading volume of 871.73K shares, PRQR reached a trading volume of 88495958 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about ProQR Therapeutics N.V. [PRQR]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PRQR shares is $1.47 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PRQR stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for ProQR Therapeutics N.V. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 22, 2022. While these analysts kept the previous recommendation, Citigroup dropped their target price from $37 to $1.70. The new note on the price target was released on February 14, 2022, representing the official price target for ProQR Therapeutics N.V. stock. Previously, the target price had yet another drop from $20 to $3, while Stifel kept a Hold rating on PRQR stock.

The Average True Range (ATR) for ProQR Therapeutics N.V. is set at 0.24, with the Price to Sales ratio for PRQR stock in the period of the last 12 months amounting to 48.88. The Price to Book ratio for the last quarter was 2.78, with the Price to Cash per share for the same quarter was set at 1.40.

How has PRQR stock performed recently?

ProQR Therapeutics N.V. [PRQR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 62.65. With this latest performance, PRQR shares gained by 100.00% in over the last four-week period, additionally plugging by 297.06% over the last 6 months – not to mention a drop of -67.11% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRQR stock in for the last two-week period is set at 86.90, with the RSI for the last a single of trading hit 89.78, and the three-weeks RSI is set at 84.75 for ProQR Therapeutics N.V. [PRQR]. The present Moving Average for the last 50 days of trading for this stock 1.1900, while it was recorded at 1.8300 for the last single week of trading, and 0.9000 for the last 200 days.

ProQR Therapeutics N.V. [PRQR]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and ProQR Therapeutics N.V. [PRQR] shares currently have an operating margin of -4300.89. ProQR Therapeutics N.V.’s Net Margin is presently recorded at -4551.03.

Return on Equity for this stock declined to -73.09, with Return on Assets sitting at -40.56.

ProQR Therapeutics N.V.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.90 and a Current Ratio set at 3.90.

Insider trade positions for ProQR Therapeutics N.V. [PRQR]

There are presently around $57 million, or 42.30% of PRQR stock, in the hands of institutional investors. The top three institutional holders of PRQR stocks are: PRIVIUM FUND MANAGEMENT B.V. with ownership of 5,344,446, which is approximately 0% of the company’s market cap and around 7.76% of the total institutional ownership; ADAGE CAPITAL PARTNERS GP, L.L.C., holding 3,300,000 shares of the stock with an approximate value of $8.91 million in PRQR stocks shares; and OPALEYE MANAGEMENT INC., currently with $8.41 million in PRQR stock with ownership of nearly 13.686% of the company’s market capitalization.

Positions in ProQR Therapeutics N.V. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 16 institutional holders increased their position in ProQR Therapeutics N.V. [NASDAQ:PRQR] by around 1,519,008 shares. Additionally, 29 investors decreased positions by around 2,421,244 shares, while 15 investors held positions by with 17,302,661 shares. The mentioned changes placed institutional holdings at 21,242,913 shares, according to the latest SEC report filing. PRQR stock had 8 new institutional investments in for a total of 929,310 shares, while 13 institutional investors sold positions of 687,977 shares during the same period.


Please enter your comment!
Please enter your name here